Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by MerckCompany expands preclinical development operationsBOULDER, Colo., December 10, 2024-- Ambrosia Biosciences Inc. ('Ambrosia'), today announced the successful second closing of its Series A financing. This closing was led by Merck, known as MSD outside the United States and Canada, with additional participation from existing investors BVF Partners and Boulder Ventures.

。此次交割由默克牵头，在美国和加拿大以外被称为MSD，现有投资者BVF Partners和Boulder Ventures也参与了此次交割。

This additional capital brings Ambrosia's total Series A financing to $25MM..

这笔额外资金使安布罗西亚的A系列融资总额达到2500万美元。。

'We are excited to have participation from Merck for this financing,' said Nick Traggis, Founder and CEO of Ambrosia. 'We are confident that orally administered, small molecule therapies will play a central role in shaping the next generation of treatments for obesity and metabolic disorders.'

安布罗西亚（Ambrosia）创始人兼首席执行官尼克·特拉吉斯（NickTraggis）说，我们很高兴默克能参与此次融资我们相信，口服小分子疗法将在塑造下一代肥胖和代谢紊乱治疗方法方面发挥核心作用。”

The proceeds from the financing will be used to further Ambrosia's drug discovery efforts as it initiates preclinical development operations at the previous Array BioPharma campus in Boulder, CO. Traggis added, 'The Ambrosia team has made impressive progress with our CRO partners, and we're now poised to accelerate these efforts even further with the added capabilities of our in-house medicinal chemistry and biology teams.'.

融资的收益将用于进一步Ambrosia的药物发现工作，因为它在之前位于科罗拉多州博尔德的Array BioPharma校区启动了临床前开发业务。Traggis补充说，“Ambrosia团队与我们的CRO合作伙伴取得了令人印象深刻的进展，我们现在准备通过我们内部药物化学和生物学团队的附加能力进一步加速这些努力。”

About Ambrosia Biosciences Inc.

关于Ambrosia Biosciences Inc。

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. For more information, please visit www.ambrosiabiosciences.comContact:

Ambrosia Biosciences Inc.是一家私营药物发现公司，开发口服小分子疗法治疗肥胖症和其他代谢紊乱。有关更多信息，请访问www.ambrosiabiosciences.com联系方式：

Media Contact

媒体联系人

Faith Clauson

信仰克劳森

(720) 841 - 3826

(720) 841 - 3826

PR@ambrosia.health

PR@ambrosia.health

Media Contact

媒体联系人

Faith Clauson, Ambrosia Biosciences, 1 7208413826, PR@ambrosia.health, https://ambrosiabiosciences.com/

Faith Clauson，Ambrosia Biosciences，1 7208413826，PR@ambrosia.health，https://ambrosiabiosciences.com/